Not Yet RecruitingNot Applicable

Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose

90 participantsStarted 2026-06-15

Plain-language summary

Assessing the effects of a nutraceutical supplement (Berbevis™) in adults with impaired fasting glucose (100-126 mg/dL) and BMI between 25 and 35. Ninety participants will be assigned to three parallel groups receiving Berbevis™ at increasing daily doses (500 mg, 750 mg, and 1000 mg) for 2 months.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * fasting blood glucose between 100 and 126 mg/dl * BMI between 25 and 35 kg/m\^2 Exclusion Criteria: * Fasting blood glucose below 100 mg/dl * BMI \< 25 or \> 35 kg/m\^2

What they're measuring

Change in fasting blood glucose levels from baseline after 4 weeks of Berbevis™ supplementation

Timeframe: 4 weeks

Trial details

NCT IDNCT06955234

SponsorAzienda di Servizi alla Persona di Pavia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-15

View on ClinicalTrials.gov More Impaired Fasting Glucose (IFG) trials